Suchergebnisse - (Standardsuche:"novel coronavirus" OR Covid OR "Sars-CoV" OR "CoV-2" OR ncov)

PubPharm (942)

671

The characteristics and predictive role of lymphocyte subsets in COVID-19 patients

enthalten in: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases | 2020

von Zhang, W. | Li, L. | Liu, J. | +7

672

SARS-CoV-2 clearance in COVID-19 patients with Novaferon treatment : A randomized, open-label, parallel-group trial

enthalten in: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases | 2020

von Zheng, F. | Zhou, Y. | Zhou, Z. | +21

CommentIn: Int J Infect Dis. 2021 Feb;103:297. - PMID 33248244

673

Asymptomatic infection by SARS-CoV-2 in healthcare workers : A study in a large teaching hospital in Wuhan, China

enthalten in: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases | 2020

von Zhao, D. | Wang, M. | Wang, M. | +9

674

A call for strengthened evidence on targeted, non-pharmaceutical interventions against COVID-19 for the protection of vulnerable individuals in sub-Saharan Africa

enthalten in: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases | 2020

von Colebunders, R. | Siewe Fodjo, J. | Vanham, G. | +1

675

Clarifying the record on hydroxychloroquine for the treatment of patients hospitalized with COVID-19

enthalten in: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases | 2020

von Rosenberg, E. | Holtgrave, D. | Udo, T.

CommentOn: Int J Infect Dis. 2020 Aug;97:396-403. - PMID 32623082

676

The continued dilemma about the usage of hydroxychloroquine : Respite is in randomized control trials

enthalten in: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases | 2020

von Malviya, A.

CommentOn: Int J Infect Dis. 2020 Aug;97:396-403. - PMID 32623082

677

Problems with the analysis in "Treatment with Hydroxychloroquine, Azithromycin, and Combination in Patients Hospitalized with COVID-19"

enthalten in: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases | 2020

von Atkinson, J.

CommentOn: Int J Infect Dis. 2020 Aug;97:396-403. - PMID 32623082

678

Effectiveness of hydroxychloroquine in COVID-19 disease : A done and dusted deal?

enthalten in: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases | 2020

von d'Arminio Monforte, A. | Tavelli, A. | Bai, F. | +2

CommentOn: Int J Infect Dis. 2020 Aug;97:396-403. - PMID 32623082

679

Early identification of COVID-19 cytokine storm and treatment with anakinra or tocilizumab

enthalten in: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases | 2020

von Langer-Gould, A. | Smith, J. | Gonzales, E. | +5

CommentIn: Int J Infect Dis. 2020 Dec;101:247-248. - PMID 33011285

680

Possible synergistic effects of hydroxychloroquine and steroids in COVID-19, time for a nuanced approach. Comment on Arshad et al

enthalten in: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases | 2020

von Wiseman, D.

CommentOn: Int J Infect Dis. 2020 Aug;97:396-403. - PMID 32623082